Zai Lab (ZLAB) Expected to Release Earnings on Thursday

Zai Lab (NASDAQ:ZLAB) is anticipated to issue its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Zai Lab to post earnings of ($0.5918) per share and revenue of $107.90 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.

Zai Lab (NASDAQ:ZLAB) last posted its quarterly earnings data on Tuesday, June 30th. The company reported ($0.50) earnings per share (EPS) for the quarter. Zai Lab had a negative net margin of 41.86% and a negative return on equity of 27.43%. The firm had revenue of $106.31 million for the quarter. On average, analysts expect Zai Lab to post ($2.37) EPS for the current fiscal year and ($2.36) EPS for the next fiscal year.

Zai Lab Price Performance

NASDAQ ZLAB opened at $21.96 on Wednesday. The company’s fifty day simple moving average is $24.78 and its 200-day simple moving average is $20.98. Zai Lab has a 52 week low of $15.96 and a 52 week high of $27.50.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zai Lab in a research note on Tuesday, October 27th. Cantor Fitzgerald reissued an “overweight” rating on shares of Zai Lab in a research report on Tuesday, October 6th. Wall Street Zen upgraded Zai Lab from a “sell” rating to a “hold” rating in a research note on Saturday, September 26th. Citigroup raised their target price on Zai Lab from $44.00 to $45.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Finally, Zacks Research raised Zai Lab from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 7th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $37.25.

Insiders Place Their Bets

In other Zai Lab news, Director William Lis sold 8,506 shares of the company’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $25.00, for a total transaction of $212,650.00. Following the sale, the director owned 41,931 shares in the company, valued at $1,048,275. This represents a 16.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders sold 9,385 shares of company stock valued at $235,145 over the last three months. 4.88% of the stock is owned by insiders.

About Zai Lab

Zai Lab Ltd. (NASDAQ:ZLAB) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. Its research and development activities have included oncology, autoimmune and inflammatory disorders, neuroscience, infectious diseases and other areas of significant unmet medical need.

Founded in 2014, Zai Lab has built its business through a combination of internally developed programs and licensing or collaboration agreements with international pharmaceutical and biotechnology companies.